1.6500 0.00 (0.00%)
After hours: 4:17PM EST
|Bid||1.5700 x 1400|
|Ask||1.6600 x 1200|
|Day's range||1.6000 - 1.7300|
|52-week range||1.2900 - 14.0000|
|Beta (5Y monthly)||1.33|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.31|
CymaBay Therapeutics, Inc. (CBAY) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
In 2017 Sujal Shah was appointed CEO of CymaBay Therapeutics, Inc. (NASDAQ:CBAY). This analysis aims first to contrast...
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) shareholders might be concerned after seeing the share price drop 28% in the...
If you own shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) then it's worth thinking about how it contributes to the...
CymaBay Therapeutics (CBAY) is currently enrolling patients in its Phase 3 registrational trial, ENHANCE, to evaluate the use of its investigational PPARδ (peroxisome proliferator-activated receptor delta) agonist, seladelpar, in PBC (primary biliary cholangitis).
CymaBay Therapeutics (CBAY) closed at $6.17 on June 12, 1.98% higher than its previous close, 28.01% above its 52-week low of $4.82, and 58.87% below its 52-week high of $15.
Intercept Pharmaceuticals (ICPT) closed at $80.99 on June 12, 0.90% higher than its previous close, 10.93% above its 52-week low of $73.01, and 39.44% below its 52-week high of $133.74.
This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. One bright shining sta...